Skip to main content
Skip to main content
Normal View Dyslexic View

Comment on: Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study

BJSA
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Correspondence to: Sabaretnam Mayilvaganan (email: drretnam@gmail.com)
Additional Professor
Department of Endocrine Surgery
Sanjay Gandhi Postgraduate Institute of Medical Sciences
India
_______
BJS, https://doi.org/10.1093/bjs/znae178, published 30 August 2024
_______
Dear Editor
The article by Partelli S et al.1 caught our attention and was discussed in our Journal Club. We commend the authors on their groundbreaking research. Both the patient and the treating physician may find it difficult to decide on the best course of treatment for non-functioning pancreatic neuroendocrine tumours, as well as to weigh the potential benefits and drawbacks of a given approach. Neoadjuvant peptide receptor radionucleotide therapy is a new idea for treating non-functioning pancreatic tumours, and it may reduce comorbidities that would otherwise arise from extensive and challenging surgery2,3.
Multicentre research is an alternative to have a sufficient number of patients because these tumours are uncommon. Readers might find these few questions interesting that were raised at our Journal Club: (i) functionality in a neuroendocrine tumour is a debate in itself4; (ii) is there any controversy regarding the functionality of a neuroendocrine tumour in patients included in this study? (iii) which hormone tests were performed to rule out functionality? (iv) did the fibrosis and alterations brought on by neoadjuvant 177Lu-1-enabled DOTA octreotide therapy make surgical resections more challenging for the surgical team?
References
Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U et al. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. BJS 2024;111; doi: https://doi.org/10.1093/bjs/znae178.
Li Y, Fan Z, Zhang F, Yang J, Shi M, Liu S, Meng Y, Zhan H. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Frontiers in Oncology 2022;12:981575.
Perysinakis I, Aggeli C, Kaltsas G, Zografos GN. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality? Hormones 2016;15:15-22.
Granberg D. Biochemical testing in patients with neuroendocrine tumors. Neuroendocrine Tumors: A Multidisciplinary Approach 2015;44:24-39.
Copied!